USPTO Issues Final Rejection of Magnolia Medical’s ‘483 Patent at Issue in Litigation

Kurin, Inc. Reports Record Revenue for Q3 2023

Kurin, Inc. Named 2023 Diverse Supplier of the Year by Vizient

USPTO Rejects Patent Claims Asserted by Magnolia Medical, Inc. against Kurin, Inc.

Delaware Federal Court Issues a Stay Order in Patent Dispute between Magnolia Medical and Kurin, Inc.

Kurin Launches Kurin Jet, Redefining the Blood Culture Contamination Device Market

USPTO Agrees to Kurin’s Request to Review Validity of Magnolia Medical’s ‘483 Patent

Kurin Receives 510k from the FDA with Indication to Reduce Blood Culture Contaminations

Kurin Commends the CDC for Their Recent Publication on Blood Culture Contamination

ENA Welcomes Kurin to 2023 Corporate Engagement Council

Kurin Announces Kurin Jet, A Quantum Leap Forward in Devices Designed to Address Blood Culture Contamination

Kurin, Inc. Reports Record Revenue for 2022

Kurin, Inc. Announces Successful FDA Audit

Kurin, Inc. Provides Update on Litigation Activity

Kurin, Inc. Announces Full Scale Manufacturing of Push-button Needle

Kurin, Inc. Statement Regarding Patent Litigation

U.S. District Court Enters Judgment of No Infringement of Patent Asserted Against Kurin Inc. by Magnolia Medical Technologies, Inc.

Kurin, Inc. Announces Launch of Its Proprietary Push-button Needle System

Kurin, Inc. Announces Agreement with AllSpire Health GPO to Impact Contaminated Blood Cultures

Kurin, Inc. Reports Record Sales for Q4 and Total 2021 Revenues

1 2 3

ML-021 Rev A